{
  "meta": {
    "title": "14_Diabetes_Mellitus_Types_Clinical_Features_And_Management",
    "url": "https://brainandscalpel.vercel.app/14-diabetes-mellitus-types-clinical-features-and-management-5c0301df.html",
    "scrapedAt": "2025-11-30T12:28:25.384Z"
  },
  "questions": [
    {
      "text": "Which of the following is not a clinical feature of diabetes mellitus?",
      "choices": [
        {
          "id": 1,
          "text": "Weight loss"
        },
        {
          "id": 2,
          "text": "Osmotic diuresis"
        },
        {
          "id": 3,
          "text": "Weight gain"
        },
        {
          "id": 4,
          "text": "Hypovolemia"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Weight loss</strong> is a clinical feature of <strong>diabetes mellitus</strong>, not weight gain.</p>\n<p><strong>Diabetes mellitus</strong>&nbsp;refers to a group of common metabolic disorders that result in&nbsp;<strong>hyperglycemia</strong>. It causes the following&nbsp;<strong>classical triad</strong> of symptoms:</p>\n<ul>\n<li><strong>Polyuria</strong> - due to osmotic diuresis</li>\n<li><strong>Polydipsia</strong> - triggered by the resulting hypovolemia</li>\n<li><strong>Weight loss</strong> - due to catabolic state</li>\n</ul>\n<p>Note: <strong>Obesity</strong> is a<strong> risk factor, not a symptom&nbsp;</strong>of&nbsp;type 2 diabetes mellitus and plays a role in its pathogenesis. Increase in the adipocyte mass leads to an increase in the level of circulating free fatty acids. Free fatty acids impair glucose utilization in skeletal muscles, promote glucose production by the liver, and impair beta-cell function.&nbsp;</p><hr><h3>Related Pearl: Types of Diabetes mellitus</h3><p>I. <strong>Type 1 diabetes</strong>:<strong>&nbsp;</strong>Beta cell destruction, usually leading to absolute insulin deficiency</p>\n<ul>\n<li>Immune-mediated</li>\n<li>Idiopathic</li>\n</ul>\n<p>II. <strong>Type 2 diabetes</strong>: Insulin resistance with relative insulin deficiency</p>\n<p>III.&nbsp;<strong>Other specific types</strong> of diabetes</p>\n<ul>\n<li>Genetic defects of beta cell development or function\n<ul>\n<li><strong>MODY &ndash; </strong>Maturity Onset Diabetes of Young</li>\n</ul>\n</li>\n<li>Genetic defects in insulin action\n<ul>\n<li>Type A insulin resistance</li>\n<li>Leprechaunism</li>\n<li>Rabson-Mendenhall syndrome Lipodystrophy syndromes</li>\n</ul>\n</li>\n<li>Diseases of the exocrine pancreas\n<ul>\n<li>Pancreatitis</li>\n<li>Neoplasia</li>\n<li>Cystic fibrosis</li>\n<li>Hemochromatosis</li>\n</ul>\n</li>\n<li>Endocrinopathies\n<ul>\n<li>Acromegaly</li>\n<li>Cushing&rsquo;s syndrome</li>\n<li>Glucagonoma</li>\n<li>Pheochromocytoma</li>\n<li>Hyperthyroidism</li>\n</ul>\n</li>\n<li>Infections\n<ul>\n<li>Congenital rubella</li>\n<li>Cytomegalovirus</li>\n<li>Coxsackievirus</li>\n</ul>\n</li>\n<li>Uncommon forms of immune-mediated diabetes\n<ul>\n<li>&ldquo;Stiff-person&rdquo; syndrome</li>\n<li>Anti-insulin receptor antibodies</li>\n</ul>\n</li>\n<li>Genetic syndromes sometimes associated with diabetes\n<ul>\n<li>Wolfram&rsquo;s syndrome</li>\n<li>Down&rsquo;s syndrome, Klinefelter&rsquo;s syndrome, Turner&rsquo;s syndrome</li>\n</ul>\n</li>\n</ul>\n<p>IV.<strong> Gestational diabetes mellitus (GDM)</strong></p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB1881",
      "difficulty": "medium"
    },
    {
      "text": "A 4-year-old boy is brought to the OPD by his worried mother as he urinates more than ten times a day and is always drinking water. She also reports that despite eating more than his brother did at that age, he is not gaining any weight. Random blood glucose is 252 mg/dl. Which of the following statements is true about this condition?",
      "choices": [
        {
          "id": 1,
          "text": "Antibodies against zinc transporters may be present"
        },
        {
          "id": 2,
          "text": "It is non-insulin dependent"
        },
        {
          "id": 3,
          "text": "It is associated with a strong family history"
        },
        {
          "id": 4,
          "text": "Insulin-resistance is the hallmark for pathogenesis"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>This clinical scenario is suggestive of<strong> type 1 diabetes&nbsp;</strong>mellitus. It is an <strong>autoimmune disease </strong>associated&nbsp;with the following immunologic markers:</p>\n<ul>\n<li><strong>Antibodies against zinc transporter</strong>&nbsp;(ZnT-8)</li>\n<li>Islet cells antibodies (ICA)</li>\n<li>Anti-glutamic acid decarboxylase antibodies (GAD)</li>\n<li>Insulin autoantibodies (IAA)</li>\n</ul><hr><h3>Related Pearl: Comparative Features of Type I and Type II Diabetes mellitus</h3><table>\n<tbody>\n<tr>\n<td>\n<p>&nbsp;</p>\n</td>\n<td>\n<p><strong>Type 1 DM</strong></p>\n</td>\n<td>\n<p><strong>Type 2 DM</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Etiology</strong></p>\n</td>\n<td>\n<p>Autoimmune</p>\n</td>\n<td>\n<p>Insulin resistance which later leads to impaired insulin secretion</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Age at onset</strong></p>\n</td>\n<td>\n<p>Usually young children</p>\n</td>\n<td>\n<p>Adult</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>HLA association</strong></p>\n</td>\n<td>\n<p><strong>DR3, DR4</strong></p>\n</td>\n<td>\n<p>No HLA association</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Body weight</strong></p>\n</td>\n<td>\n<p>Normal / Underweight</p>\n</td>\n<td>\n<p><strong>Obese</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Family history</strong></p>\n</td>\n<td>\n<p>May or may not be positive</p>\n</td>\n<td>\n<p>Usually<strong> strongly positive</strong>&nbsp;</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Presentation</strong></p>\n</td>\n<td>\n<p>Abrupt</p>\n</td>\n<td>\n<p>Gradual or symptomatic</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Insulin requirement</strong></p>\n</td>\n<td>\n<p>Absolute</p>\n</td>\n<td>\n<p>Oral hypoglycemics, later insulin</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Serum insulin level / C peptide level</strong></p>\n</td>\n<td>\n<p>Low</p>\n</td>\n<td>\n<p>High</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>&nbsp;</strong></p>\n<p><strong>Clinical Features</strong></p>\n</td>\n<td>\n<p><strong>Diabetic ketoacidosis</strong> is common&nbsp;</p>\n<p>It is associated with other autoimmune diseases like:</p>\n<p><strong>Thyroid disorders</strong></p>\n<ul>\n<li>Addison's disease</li>\n<li>Rheumatoid arthritis</li>\n<li>Schmidt syndrome/ Polyglandular failure syndrome</li>\n</ul>\n</td>\n<td>\n<p><strong>Non-ketotic hyperosmolar coma</strong> is common</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB1897",
      "difficulty": "medium"
    },
    {
      "text": "Which chromosome contains the major susceptible gene for type 1 diabetes mellitus?",
      "choices": [
        {
          "id": 1,
          "text": "1"
        },
        {
          "id": 2,
          "text": "4"
        },
        {
          "id": 3,
          "text": "6"
        },
        {
          "id": 4,
          "text": "12"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The major susceptibility gene for <strong>type 1 diabetes&nbsp;</strong>mellitus&nbsp;is located in the HLA region of&nbsp;<strong>chromosome 6</strong>.</p>\n<p>Type I diabetes mellitus occurs in <strong>genetically susceptible</strong> individuals and is usually <strong>triggered</strong> by <strong>infections</strong>. The HLA complex is most commonly involved. The common HLA associations include:</p>\n<ul>\n<li><strong>Causative -</strong>&nbsp;HLA-DQA1*0501 and DQB*0201</li>\n<li><strong>Protective</strong> - HLA-DQA1*0102,&nbsp;DQB1*0602, DRB1*1501</li>\n</ul>\n<p>Other genomic associations of type I diabetes mellitus include the&nbsp;<strong>CTLA-4 gene </strong>and<strong> IL-2 receptor.</strong></p>\n<p>Type 2 diabetes mellitus&nbsp;is associated with mutations in the calpain-10 gene on chromosome 2. It results in insulin resistance.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB1900",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following mechanisms is predominantly responsible for an increase in the fasting plasma glucose level of patients with type 2 diabetes mellitus?",
      "choices": [
        {
          "id": 1,
          "text": "Increased hepatic gluconeogenesis"
        },
        {
          "id": 2,
          "text": "Decreased peripheral uptake of glucose"
        },
        {
          "id": 3,
          "text": "Decreased glycogenesis in muscles"
        },
        {
          "id": 4,
          "text": "Decreased hepatic glycogenesis"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>In type 2 diabetes mellitus increased <strong>fasting blood sugar</strong> is predominantly due to increased <strong>hepatic gluconeogenesis.</strong></p>\n<p>In the postprandial period, there is a rise in peripheral blood glucose levels. Due to <strong>insulin resistance</strong> in type 2 diabetes mellitus, there is <strong>reduced</strong> <strong>peripheral uptake</strong> of glucose by insulin-sensitive tissues like the liver and skeletal muscles. This results in <strong>reduced glucose utilization</strong> by skeletal muscles as well as <strong>reduced glycogenesis</strong> in the liver and skeletal muscles. This results in <strong>increased postprandial</strong> <strong>plasma glucose</strong> levels.<br />Increased hepatic glucose output predominantly accounts for increased FPG levels, whereas decreased peripheral glucose utilization results in postprandial hyperglycemia.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB1906",
      "difficulty": "medium"
    },
    {
      "text": "A 22-year-old woman presents with fatigue and weight loss for the past 6 months. She tells you that her father is also a diabetic. Further evaluation reveals the following. What is the most likely diagnosis?<div class='question-desc-html'><p>Body mass index - 21 kg/m<sup>2</sup></p>\n<p>Fasting blood sugar - 252 mg/dl</p>\n<p>Glycosylated hemoglobin - 8.2%</p>\n<p>Urinalysis for ketones - Negative</p>\n<p> </p></div>",
      "choices": [
        {
          "id": 1,
          "text": "Type 2 diabetes mellitus"
        },
        {
          "id": 2,
          "text": "Maturity-onset diabetes of the young"
        },
        {
          "id": 3,
          "text": "Type I diabetes mellitus"
        },
        {
          "id": 4,
          "text": "Latent autoimmune diabetes in adults"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>This clinical scenario is suggestive of maturity-onset diabetes of the young (<strong>MODY</strong>). </p>\n<p>MODY is a <strong>monogenic</strong> form of<strong> diabetes</strong> <strong>mellitus</strong> that is transmitted in an <strong>autosomal dominant</strong> fashion. It affects young adults<strong> &lt; 25 years </strong>of age. It occurs due to reduced insulin secretion. Etiological factors of type 1 and 2 diabetes such as insulin resistance, obesity, and antibodies are not associated with this condition.</p>\n<p><strong>Stable hyperglycemia</strong> is usually seen, hence complications like diabetic ketoacidosis are uncommon. Macrovascular complications like hyperlipidemia or hypertension are not seen. It is treated with <strong>sulfonylureas.</strong></p>\n<p>Latent autoimmune diabetes in adults (LADA) is a form of type 1 diabetes that occurs between 30-50 years of age.</p><hr><h3>Related Pearl: Comparative Features between MODY and Type 2 DM</h3><table>\n<tbody>\n<tr>\n<td>\n<p>&nbsp;</p>\n</td>\n<td>\n<p><strong>Type 2 DM</strong></p>\n</td>\n<td>\n<p><strong>MODY</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Age of onset</strong></p>\n</td>\n<td>\n<p>Predominantly middle to old age</p>\n</td>\n<td>\n<p>Predominantly young (&lt; 25 years)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Pathology</strong></p>\n</td>\n<td>\n<p>Beta cell dysfunction</p>\n<p>Insulin resistance</p>\n</td>\n<td>\n<p>Only Beta cell dysfunction</p>\n<p>No insulin resistance</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Family history</strong></p>\n</td>\n<td>\n<p>Positive</p>\n<p>Inheritance - Polygenic&nbsp;</p>\n<p>Vertical transmission through <strong>successive generations</strong> is <strong>not essential </strong>for diagnosis</p>\n</td>\n<td>\n<p>Positive</p>\n<p>Inheritance &ndash; Monogenic / <strong>Autosomal dominant</strong>&nbsp;</p>\n<p>Vertical transmission through at <strong>least two successive generation</strong> (ideally three) is <strong>essential</strong> for diagnosis</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Insulin dependence</strong></p>\n</td>\n<td>\n<p>Non-insulin dependent</p>\n</td>\n<td>\n<p>Non-insulin dependent</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Obesity</strong></p>\n</td>\n<td>\n<p>Common</p>\n</td>\n<td>\n<p>Uncommon</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>DKA</strong></p>\n</td>\n<td>\n<p>Uncommon</p>\n</td>\n<td>\n<p>Uncommon</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Serum insulin level</strong></p>\n</td>\n<td>\n<p>High</p>\n</td>\n<td>\n<p>Low</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB1916",
      "difficulty": "medium"
    },
    {
      "text": "All of the following are true about maturity-onset diabetes of the young (MODY) except:",
      "choices": [
        {
          "id": 1,
          "text": "It is an autosomal-dominant trait"
        },
        {
          "id": 2,
          "text": "MODY 4 is the most common form"
        },
        {
          "id": 3,
          "text": "Diabetic ketoacidosis is uncommon"
        },
        {
          "id": 4,
          "text": "Insulinopenia is present"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>MODY 3</strong> is the <strong>most common</strong> form of maturity-onset diabetes of the young (MODY), accounting for two-thirds of all the cases.</p>\n<p>MODY is a <strong>monogenic</strong>&nbsp;form of <strong>diabetes mellitus</strong> that is transmitted in an&nbsp;<strong>autosomal dominant</strong> fashion. It&nbsp;affects young adults<strong> &lt;25 years&nbsp;</strong>of age. There are a total of 11 types of MODY based on mutations involves. Some of the affected genes include:</p>\n<ul>\n<li>Types 1,3,5:&nbsp;<strong>HNF</strong>&nbsp;(Hepatocyte nuclear transcription factor) mutation</li>\n<li>Type 2: <strong>Glucokinase</strong> mutation</li>\n<li>Type 4: <strong>IPF 1</strong>&nbsp;(Insulin Promotor Factor-1) mutation</li>\n</ul>\n<p>These mutations result in <strong>impaired</strong> glucose-induced <strong>insulin secretion&nbsp;</strong>resulting in <strong>insulinopenia</strong>.&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB1909",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following would cause type 1 diabetes in an adult patient?",
      "choices": [
        {
          "id": 1,
          "text": "Latent diabetes"
        },
        {
          "id": 2,
          "text": "Maturity-onset diabetes of the young"
        },
        {
          "id": 3,
          "text": "Brittle diabetes"
        },
        {
          "id": 4,
          "text": "Latent autoimmune diabetes in adults"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Type 1 diabetes</strong> mellitus in an&nbsp;<strong>adult</strong>&nbsp;is suggestive of latent autoimmune diabetes in adults (<strong>LADA</strong>).&nbsp;</p>\n<p>LADA is common in <strong>thin-built</strong> adults between<strong>&nbsp;30-50 years</strong> and is associated with <strong>autoantibodies</strong>. As the progression of the disease is less rapid than in children, clinical features may mimic type 2 diabetes. However, patients usually require <strong>insulin</strong> treatment <strong>within 5 years</strong>.</p>\n<p>Option A: Patients with latent diabetes&nbsp;become diabetic under stressful&nbsp;conditions. However, upon <strong>removal of stress</strong>, they become <strong>non-diabetic</strong>.</p>\n<p>Option B: <strong>MODY</strong> or maturity-onset diabetes of the young is a monogenic form of diabetes that occurs <strong>&lt; 25 years</strong>. There is impaired insulin secretion, but <strong>no antibodies</strong>.</p>\n<p>Option C: Brittle diabetes is seen in <strong>children</strong> with<strong> type 1 DM</strong>. It presents with <strong>wide fluctuation</strong> in blood sugar levels.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB1911",
      "difficulty": "medium"
    },
    {
      "text": "Patients with all of the following conditions can develop diabetes mellitus except:",
      "choices": [
        {
          "id": 1,
          "text": "Hemochromatosis"
        },
        {
          "id": 2,
          "text": "Prader-Willi syndrome"
        },
        {
          "id": 3,
          "text": "Fragile X syndrome"
        },
        {
          "id": 4,
          "text": "Friedrich’s ataxia"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>Fragile X syndrome is not associated with <strong>diabetes mellitus</strong>.</p>\n<p>Genetic syndromes associated with diabetes include:</p>\n<ul>\n<li><strong>Prader-Willi syndrome</strong></li>\n<li><strong>Friedreich&rsquo;s ataxia</strong></li>\n<li>Wolfram&rsquo;s syndrome</li>\n<li>Down&rsquo;s syndrome</li>\n<li>Klinefelter&rsquo;s and Turner&rsquo;s syndrome</li>\n<li>Huntington&rsquo;s chorea</li>\n<li>Laurence-Moon-Biedl syndrome</li>\n<li>Myotonic dystrophy</li>\n<li>Porphyria</li>\n</ul>\n<p>Diseases of the exocrine pancreas causing diabetes:</p>\n<ul>\n<li><strong>Hemochromatosis</strong></li>\n<li>Pancreatitis</li>\n<li>Neoplasia</li>\n<li>Cystic fibrosis</li>\n</ul>\n<p>Endocrinopathies causing diabetes:</p>\n<ul>\n<li>Acromegaly</li>\n<li>Cushing&rsquo;s syndrome</li>\n<li>Glucagonoma</li>\n<li>Pheochromocytoma</li>\n<li>Hyperthyroidism</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB1914",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following patients can be diagnosed with diabetes mellitus?",
      "choices": [
        {
          "id": 1,
          "text": "A patient with RBS of 210 mg/dl"
        },
        {
          "id": 2,
          "text": "A patient with FBS of 125 mg/dl and 2-hour PPBS of 199 mg/dl"
        },
        {
          "id": 3,
          "text": "A patient with symptoms of diabetes and RBS of 192 mg/dl"
        },
        {
          "id": 4,
          "text": "A patient with HbA1c ≥ 6.5 %"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>The patient with<strong>&nbsp;HbA1c &ge; 6.5 % </strong>can be diagnosed with diabetes mellitus as this is an independent criterion for diagnosis.</p><hr><h3>Related Pearl: ADA criteria for Diagnosis of Diabetes mellitus</h3><p><strong>Any one</strong> of the following:</p>\n<ul>\n<li><strong>Symptoms</strong> of diabetes <strong>plus</strong> Random Blood Glucose concentration <strong>&ge;</strong> <strong>200 mg/dL.</strong></li>\n<li><strong>Fasting plasma</strong> glucose <strong>&ge;</strong> <strong>126 </strong>mg/dL.&nbsp;Fasting is defined as no caloric intake for at least 8 hours.</li>\n<li>Haemoglobin <strong>A1c </strong><strong>&ge;6.</strong><strong>5%</strong></li>\n<li><strong>2-hour</strong> plasma <strong>glucose </strong><strong>&ge;</strong> <strong>200 mg/dL</strong> during an <strong>oral glucose tolerance test.</strong></li>\n</ul>\n<p>Note: In the absence of unequivocal hyperglycemia and acute metabolic decompensation, these criteria should be <strong>confirmed by repeat testing</strong> on a different day.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB1921",
      "difficulty": "easy"
    },
    {
      "text": "A 46-year-old man presents to his physician for a routine health evaluation. He is concerned that he might have diabetes as his three brothers have all been diagnosed with diabetes. He does not have any complaints. Which of the following tests can be employed in this patient?<div class='question-desc-html'><ol>\n<li>Fasting blood glucose</li>\n<li>Random blood glucose</li>\n<li>Oral glucose tolerance test</li>\n<li>Glycosylated hemoglobin level</li>\n<li>Postprandial blood glucose</li>\n</ol></div>",
      "choices": [
        {
          "id": 1,
          "text": "1, 2, 4"
        },
        {
          "id": 2,
          "text": "1, 4"
        },
        {
          "id": 3,
          "text": "2, 3, 5"
        },
        {
          "id": 4,
          "text": "4, 5"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>HbA1c and fasting blood glucose are used for <strong>screening</strong> <strong>diabetes</strong> mellitus in <strong>asymptomatic</strong> individuals.</p>\n<div class=\"ng-scope\">\n<div class=\"ng-scope\">\n<p><strong>HbA1c</strong> refers to glycated hemoglobin and it serves as a <strong>long-term indicator</strong>&nbsp;for blood glucose levels (8 to 12 weeks).</p>\n<ul>\n<li>Normal&nbsp;<strong>&lt; 5.7 %</strong></li>\n<li>Abnormal glucose homeostasis: <strong>5.</strong><strong>7 to 6.4 %</strong></li>\n<li>Diabetes mellitus:&nbsp;<strong>&ge; 6.5%</strong></li>\n</ul>\n<p>HbA1c also serves as a <strong>prognostic indicator</strong>&nbsp;for glycemic control.</p>\n</div>\n</div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB1922",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following can be termed impaired glucose tolerance?",
      "choices": [
        {
          "id": 1,
          "text": "Fasting blood glucose levels between 100 and 125 mg/dL"
        },
        {
          "id": 2,
          "text": "Random blood glucose levels between 140 and 199 mg/dL"
        },
        {
          "id": 3,
          "text": "Blood glucose levels between 140 and 199 mg/dL following oral glucose tolerance test"
        },
        {
          "id": 4,
          "text": "Fasting blood glucose levels between 100 and 199 mg/dL"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Impaired glucose tolerance </strong>is defined as blood glucose levels between <strong>140-199 mg/dL </strong>following an oral glucose tolerance test (<strong>OGTT</strong>)<strong>.</strong></p>\n<p>Impaired fasting glucose is when the fasting<strong> </strong>blood glucose is between 100 to 125 <span class=\"nowrap\">mg/dL.</span></p><hr><h3>Related Pearl: Abnormal Glucose Homeostasis</h3><p>Individuals without overt diabetes can have <strong>abnormal glucose homeostasis.&nbsp;</strong>It is also&nbsp;called <strong>prediabetes</strong> or intermediate hyperglycemia. These people are at an increased risk of developing diabetes<strong>&nbsp;</strong>mellitus. Three categories of abnormal glucose homeostasis have been defined:</p>\n<ul>\n<li class=\"bulletIndent2\">Impaired glucose tolerance&nbsp;(IGT) &ndash;&nbsp;blood glucose levels between 140 and 199 mg/dL following an oral glucose challenge</li>\n<li class=\"bulletIndent2\">Impaired fasting glucose&nbsp;(IFG) &ndash; fasting<strong>&nbsp;</strong>blood glucose 100 to 125&nbsp;<span class=\"nowrap\">mg/dL</span>&nbsp;</li>\n<li class=\"bulletIndent2\">HbA1c&nbsp;&ndash; 5.7-6.4%</li>\n</ul>\n<p class=\"bulletIndent2\">Please&nbsp;note that impaired glucose tolerance and impaired fasting glucose are two distinct entities.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB1924",
      "difficulty": "medium"
    },
    {
      "text": "You are counselling an asymptomatic middle-aged woman regarding screening for diabetes mellitus. Based on the ADA recommendations, what will you tell her?",
      "choices": [
        {
          "id": 1,
          "text": "All individuals > 35 years must undergo screening every 3 years"
        },
        {
          "id": 2,
          "text": "All individuals > 50 years must undergo screening every 5 years"
        },
        {
          "id": 3,
          "text": "Oral glucose tolerance test would be performed"
        },
        {
          "id": 4,
          "text": "Random blood glucose levels would be checked"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The ADA recommends <strong>screening</strong> for <strong>type 2 diabetes</strong> mellitus in all asymptomatic individuals <strong>&gt; 35 years</strong> every <strong>3 years</strong>.</p>\n<p>The tests used for screening are:</p>\n<ul>\n<li><strong>HbA1c</strong> levels</li>\n<li><strong>Fasting</strong> blood glucose levels</li>\n</ul>\n<p>Individuals can be screened earlier if they are overweight with <strong>BMI &gt;25</strong> kg/m2 <strong>and</strong> have one of the following <strong>risk factors</strong>:</p>\n<ul>\n<li>Family history of diabetes</li>\n<li>History of cardiovascular diseases</li>\n<li>History of gestational diabetes mellitus or delivery of a baby &gt; 4 kg</li>\n<li>Obesity (BMI ≥25 kg/m<sup>2</sup>)</li>\n<li>Physical inactivity</li>\n<li>Hypertension (≥140/90 mm Hg)</li>\n<li>HDL cholesterol &lt; 35 mg/dL</li>\n<li>Triglycerides &gt;250 mg/dL</li>\n<li>Polycystic ovarian syndrome or acanthosis nigricans</li>\n</ul>\n<p>Note- If an individual has a test result near the margins of the diagnostic threshold, a close follow-up should be done and repeat the test in <strong>3–6</strong> months.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB1927",
      "difficulty": "medium"
    },
    {
      "text": "A middle-aged woman has been diagnosed with type 2 diabetes mellitus. Her HbA1c level is 11.1%. What is the initial drug of choice?",
      "choices": [
        {
          "id": 1,
          "text": "Insulin"
        },
        {
          "id": 2,
          "text": "Glimepiride"
        },
        {
          "id": 3,
          "text": "Metformin"
        },
        {
          "id": 4,
          "text": "Sitagliptin"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Insulin</strong>&nbsp;is the best<strong> initial drug</strong>&nbsp;of choice when <strong>HbA1c is &gt; 9%</strong> at diagnosis<strong>.&nbsp;</strong></p>\n<p>Insulin is used in the treatment of type 2 diabetes in the following cases:</p>\n<ul>\n<li>Inadequate glycemic control with 2 or more oral agents</li>\n<li>HbA1c &gt; 9% at diagnosis</li>\n</ul>\n<p>In patients with <strong>HbA1c &lt; 9%</strong>, <strong>metformin</strong> is the drug of choice.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/321a1fd668314bf094066c62c1954768x1280x2077.JPEG\" alt=\"Explanation Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB1928",
      "difficulty": "easy"
    },
    {
      "text": "A 45-year-old woman was brought to the emergency department by her relatives after she suffered a brief, seizure-like episode. They tell you that she is taking an oral medication for diabetes. On examination, the patient was disoriented, and CBG was 45 mg/dl. Which of the following drugs most likely played a role in the patient’s current presentation?",
      "choices": [
        {
          "id": 1,
          "text": "Metformin"
        },
        {
          "id": 2,
          "text": "Pioglitazone"
        },
        {
          "id": 3,
          "text": "Sitagliptin"
        },
        {
          "id": 4,
          "text": "Repaglinide"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Repaglinide</strong> is an <strong>insulin secretagogue</strong> and hence poses the risk of causing&nbsp;<strong>hypoglycemia</strong>.</p>\n<p>Drugs that can cause hypoglycemia (insulin secretagogues):</p>\n<ul>\n<li>Sulfonylureas</li>\n<li>Meglitinides: Nateglinide, Repaglinide</li>\n</ul>\n<p>The following drugs are not directly responsible for stimulating insulin secretion and hence do not cause&nbsp;hypoglycemia:</p>\n<ul>\n<li>Metformin</li>\n<li>Alpha-glucosidase inhibitor</li>\n<li>Pioglitazone</li>\n<li>DPP-4 inhibitor: Sitagliptin</li>\n</ul>\n<table>\n<tbody>\n<tr>\n<td colspan=\"3\"><strong>Management of diabetes mellitus</strong></td>\n</tr>\n<tr>\n<td><strong>Intervention</strong></td>\n<td><strong>Advantages</strong></td>\n<td><strong>Disadvantages</strong></td>\n</tr>\n<tr>\n<td>Lifestyle changes</td>\n<td>Reduced complications and mortality</td>\n<td>Insufficient for most patients within 1st year</td>\n</tr>\n<tr>\n<td>Metformin</td>\n<td>Weight neutral</td>\n<td>\n<p>GI side effects</p>\n<p>Contraindicated when GFR &lt; 45 ml/min</p>\n</td>\n</tr>\n<tr>\n<td>Insulin</td>\n<td>\n<p>Rapidly effective</p>\n<p>Lowers HbA1c more than other drugs (by 1.5-3%)</p>\n</td>\n<td>\n<p>Weight gain</p>\n<p>Hypoglycemia</p>\n</td>\n</tr>\n<tr>\n<td>GLP-1 agonists</td>\n<td>\n<p>Weight loss</p>\n<p>Reduces cardiovascular complications</p>\n</td>\n<td>GI side effects</td>\n</tr>\n<tr>\n<td>Pramlintide</td>\n<td>\n<p>Weight loss</p>\n<p>Lowers postprandial glucose</p>\n</td>\n<td>\n<p>GI side effects</p>\n<p>Hypoglycemia when used with insulin</p>\n</td>\n</tr>\n<tr>\n<td>Sulfonylureas</td>\n<td>Rapidly effective</td>\n<td>\n<p>Weight gain</p>\n<p>Hypoglycemia</p>\n</td>\n</tr>\n<tr>\n<td>Thiazolidinediones</td>\n<td>Lowers insulin requirements</td>\n<td>\n<p>Weight gain, edema,&nbsp;CHF, fractures</p>\n</td>\n</tr>\n<tr>\n<td>Meglitinides</td>\n<td>Rapidly effective</td>\n<td>\n<p>Weight gain</p>\n<p>Hypoglycemia</p>\n</td>\n</tr>\n<tr>\n<td>SGLT-2 inhibitors</td>\n<td>\n<p>Weight loss</p>\n<p>Better cardiovascular and renal outcomes</p>\n</td>\n<td>\n<p>UTI, vulval candidiasis</p>\n<p>Dehydration</p>\n<p>Euglycemic DKA</p>\n</td>\n</tr>\n<tr>\n<td>DPP-4 inhibitors</td>\n<td>Weight neutral</td>\n<td>Angioedema, urticaria</td>\n</tr>\n<tr>\n<td>Alpha-glucosidase inhibitors</td>\n<td>Weight neutral</td>\n<td>\n<p>GI flatulence</p>\n<p>Rise in LFT</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB1929",
      "difficulty": "hard"
    },
    {
      "text": "All of the following drugs can be used in the treatment of patients with type 1 diabetes except:",
      "choices": [
        {
          "id": 1,
          "text": "Acarbose"
        },
        {
          "id": 2,
          "text": "Pramlintide"
        },
        {
          "id": 3,
          "text": "Metformin"
        },
        {
          "id": 4,
          "text": "Insulin"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Metformin</strong> can <strong>only</strong> be used in the treatment of&nbsp;<strong>type 2 </strong>diabetes mellitus.</p>\n<p>Drugs that can be used for treating<strong> both type 1 </strong>and type<strong>&nbsp;2 </strong>diabetes mellitus include the following<strong>:</strong></p>\n<ul>\n<li><strong>Acarbose</strong> - reduces the breakdown of starch into sugar in the GI tract and <strong>lowers</strong> the <strong>postprandial</strong> glucose rise in both types.</li>\n<li><strong>Pramlintide</strong> - an <strong>injectable</strong> drug that enhances<strong> amylin secretion</strong> leading to <strong>reduced glucagon</strong> levels</li>\n<li>Insulin</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB1931",
      "difficulty": "medium"
    },
    {
      "text": "A 40-year-old male patient with type 2 diabetes mellitus is now diagnosed with hypertension. Which of the following antihypertensive drugs will you not prefer in this patient?",
      "choices": [
        {
          "id": 1,
          "text": "Hydrochlorthiazide"
        },
        {
          "id": 2,
          "text": "Losartan"
        },
        {
          "id": 3,
          "text": "Lisinopril"
        },
        {
          "id": 4,
          "text": "Furosemide"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Hydrochlorthiazide</strong> belongs to the <strong>thiazide</strong> group of diuretics, that can cause <strong>dyslipidemia</strong> and <strong>hyperglycemia.</strong> Hence they<strong>&nbsp;</strong>are<strong> not</strong>&nbsp;<strong>preferred</strong>&nbsp;for use in <strong>diabetic hypertensives</strong>.</p>\n<p>The antihypertensive <strong>drug</strong> <strong>of</strong> <strong>choice</strong> in diabetes mellitus include angiotensin-converting enzyme inhibitors (<strong>ACE-I</strong>) or angiotensin II receptor blockers (<strong>ARBs</strong>).</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB1932",
      "difficulty": "medium"
    },
    {
      "text": "A type 2 diabetic patient who was recently started on treatment complains of frequent urination, fever, and burning micturition. Which of the following drugs is most likely responsible for these symptoms?",
      "choices": [
        {
          "id": 1,
          "text": "Dapagliflozin"
        },
        {
          "id": 2,
          "text": "Metformin"
        },
        {
          "id": 3,
          "text": "Glipizide"
        },
        {
          "id": 4,
          "text": "Exenatide"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>This clinical scenario is suggestive of a urinary tract infection (<strong>UTI</strong>). This adverse effect occurs as a result of&nbsp;<strong>dapagliflozin&nbsp;</strong>use.</p>\n<p>The group of sodium-glucose co-transporter-2 or <strong>SGLT-2&nbsp;inhibitors&nbsp;</strong>includes drugs like dapagliflozin and canagliflozin. These drugs&nbsp;prevent glucose reabsorption in the renal tubules and cause loss of sodium and glucose.&nbsp;</p>\n<ul>\n<li>UTI - due to <strong>glucosuria</strong></li>\n<li>Dehydration<strong>&nbsp;-&nbsp;</strong>due to <strong>natriuresis</strong> and volume loss</li>\n<li><strong>Euglycemic diabetic ketoacidosis</strong> - low blood glucose levels due to glucosuria can reduce insulin release</li>\n</ul>\n<p>SGLT-2 inhibitors must be temporarily discontinued for 3-4 days before any scheduled surgery to avoid potential risk for diabetic ketoacidosis.</p>\n<table>\n<tbody>\n<tr>\n<td colspan=\"3\"><strong>Management of diabetes mellitus</strong></td>\n</tr>\n<tr>\n<td><strong>Intervention</strong></td>\n<td><strong>Advantages</strong></td>\n<td><strong>Disadvantages</strong></td>\n</tr>\n<tr>\n<td>Lifestyle changes</td>\n<td>Reduced complications and mortality</td>\n<td>Insufficient for most patients within 1st year</td>\n</tr>\n<tr>\n<td>Metformin</td>\n<td>Weight neutral</td>\n<td>\n<p>GI side effects</p>\n<p>Contraindicated when GFR &lt; 45 ml/min</p>\n</td>\n</tr>\n<tr>\n<td>Insulin</td>\n<td>\n<p>Rapidly effective</p>\n<p>Lowers HbA1c more than other drugs (by 1.5-3%)</p>\n</td>\n<td>\n<p>Weight gain</p>\n<p>Hypoglycemia</p>\n</td>\n</tr>\n<tr>\n<td>GLP-1 agonists</td>\n<td>\n<p>Weight loss</p>\n<p>Reduces cardiovascular complications</p>\n</td>\n<td>GI side effects</td>\n</tr>\n<tr>\n<td>Pramlintide</td>\n<td>\n<p>Weight loss</p>\n<p>Lowers postprandial glucose</p>\n</td>\n<td>\n<p>GI side effects</p>\n<p>Hypoglycemia when used with insulin</p>\n</td>\n</tr>\n<tr>\n<td>Sulfonylureas</td>\n<td>Rapidly effective</td>\n<td>\n<p>Weight gain</p>\n<p>Hypoglycemia</p>\n</td>\n</tr>\n<tr>\n<td>Thiazolidinediones</td>\n<td>Lowers insulin requirements</td>\n<td>\n<p>Weight gain, edema,&nbsp;CHF, fractures</p>\n</td>\n</tr>\n<tr>\n<td>Meglitinides</td>\n<td>Rapidly effective</td>\n<td>\n<p>Weight gain</p>\n<p>Hypoglycemia</p>\n</td>\n</tr>\n<tr>\n<td>SGLT-2 inhibitors</td>\n<td>\n<p>Weight loss</p>\n<p>Better cardiovascular and renal outcomes</p>\n</td>\n<td>\n<p>UTI, vulval candidiasis</p>\n<p>Dehydration</p>\n<p>Euglycemic DKA</p>\n</td>\n</tr>\n<tr>\n<td>DPP-4 inhibitors</td>\n<td>Weight neutral</td>\n<td>Angioedema, urticaria</td>\n</tr>\n<tr>\n<td>Alpha-glucosidase inhibitors</td>\n<td>Weight neutral</td>\n<td>\n<p>GI flatulence</p>\n<p>Rise in LFT</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><p><span data-sheets-value=\"{&quot;1&quot;:2,&quot;2&quot;:&quot;The FDA recently approved Ddapagliflozin oral tablets to reduce the risk of kidney function decline, in adults with chronic kidney disease who are at risk of disease progression. &quot;}\" data-sheets-userformat=\"{&quot;2&quot;:33563519,&quot;3&quot;:{&quot;1&quot;:0},&quot;4&quot;:{&quot;1&quot;:2,&quot;2&quot;:6989903},&quot;5&quot;:{&quot;1&quot;:[{&quot;1&quot;:2,&quot;2&quot;:0,&quot;5&quot;:{&quot;1&quot;:2,&quot;2&quot;:0}},{&quot;1&quot;:0,&quot;2&quot;:0,&quot;3&quot;:3},{&quot;1&quot;:1,&quot;2&quot;:0,&quot;4&quot;:1}]},&quot;6&quot;:{&quot;1&quot;:[{&quot;1&quot;:2,&quot;2&quot;:0,&quot;5&quot;:{&quot;1&quot;:2,&quot;2&quot;:0}},{&quot;1&quot;:0,&quot;2&quot;:0,&quot;3&quot;:3},{&quot;1&quot;:1,&quot;2&quot;:0,&quot;4&quot;:1}]},&quot;7&quot;:{&quot;1&quot;:[{&quot;1&quot;:2,&quot;2&quot;:0,&quot;5&quot;:{&quot;1&quot;:2,&quot;2&quot;:0}},{&quot;1&quot;:0,&quot;2&quot;:0,&quot;3&quot;:3},{&quot;1&quot;:1,&quot;2&quot;:0,&quot;4&quot;:1}]},&quot;8&quot;:{&quot;1&quot;:[{&quot;1&quot;:2,&quot;2&quot;:0,&quot;5&quot;:{&quot;1&quot;:2,&quot;2&quot;:0}},{&quot;1&quot;:0,&quot;2&quot;:0,&quot;3&quot;:3},{&quot;1&quot;:1,&quot;2&quot;:0,&quot;4&quot;:1}]},&quot;9&quot;:0,&quot;11&quot;:4,&quot;12&quot;:0,&quot;16&quot;:10,&quot;28&quot;:1}\">The FDA recently approved dapagliflozin oral tablets to reduce the risk of renal and cardiac failure in adults with chronic kidney disease who are at risk of disease progression. </span></p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB1930",
      "difficulty": "easy"
    },
    {
      "text": "A 65-year-old man is hospitalized with pneumonia. He is a known patient of type 2 diabetes. During the hospital stay, his appetite is poor and his oral intake is irregular. The physician decides to administer rapid-acting insulin based on high blood sugar values. Which of the following would he use?",
      "choices": [
        {
          "id": 1,
          "text": "Lente"
        },
        {
          "id": 2,
          "text": "Detemir"
        },
        {
          "id": 3,
          "text": "Glargine"
        },
        {
          "id": 4,
          "text": "Glulisine"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>This clinical scenario describes the <strong>sliding scale</strong> method. <strong>Rapid-acting</strong> insulins such as <strong>glulisine</strong>&nbsp;are used.</p>\n<p>Sliding scale refers to the administration of insulin as a <strong>bolus</strong> dose based on the&nbsp;blood sugar level before the meal.&nbsp;Using this principle, the insulin dose is <strong>titrated</strong> every time according to <strong>pre-meal</strong>&nbsp;<strong>glucose</strong> levels to determine insulin requirement. Hence, <strong>rapid-acting</strong> insulin is preferred.</p>\n<p>This method requires a <strong>fixed carbohydrate</strong> intake at every meal. It is used for the <strong>short-term</strong> management of <strong>hospitalized</strong> patients, especially when the frequency or quantity of food intake is very variable.</p>\n<p>It does not deliver insulin in a physiological manner, hence is not a preferred long-term strategy for glycemic control.</p><hr><h3>Related Pearl: Insulin Classification According to Duration of Action</h3><p><strong>Inhaled insulin&nbsp;(2-3 hours)</strong></p>\n<ul>\n<li>Afrezza&nbsp;</li>\n</ul>\n<p><strong>Rapid acting (3-4 hours)</strong></p>\n<ul>\n<li>Aspart</li>\n<li>Glulisine</li>\n<li>Lispro</li>\n</ul>\n<p><strong>Short acting&nbsp;(6-8 hours)</strong></p>\n<ul>\n<li>Regular</li>\n</ul>\n<p><strong>Intermediate acting (10-16 hours)</strong></p>\n<ul>\n<li>NPH</li>\n<li>Lente</li>\n</ul>\n<p><strong>Long acting&nbsp;(12-24 hours)</strong></p>\n<ul>\n<li>Detemir</li>\n<li>Glargine</li>\n<li>Degludec <strong>(24-42 hours)</strong></li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB1933",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following is incorrect about Afrezza?",
      "choices": [
        {
          "id": 1,
          "text": "It is available as a powder for inhalation"
        },
        {
          "id": 2,
          "text": "It can cause bronchospasm"
        },
        {
          "id": 3,
          "text": "It does not cause hypoglycemia"
        },
        {
          "id": 4,
          "text": "It is a rapid-acting form"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<div class=\"sect1 \">\n<p><strong>Afrezza</strong>&nbsp;is an <strong>inhalational</strong> form of insulin that can cause <strong>hypoglycemia</strong>.</p>\n<p>It is a&nbsp;<strong>rapid-acting</strong>&nbsp;form of insulin that&nbsp;is administered at the beginning of each meal. Peak levels are achieved <strong>12-15 minutes</strong> later.</p>\n<p>Adverse effects include<strong>&nbsp;</strong>hypoglycemia, cough,&nbsp;throat pain, or irritation. It may cause&nbsp;<strong>acute bronchospasm</strong>&nbsp;in patients with&nbsp;<strong>asthma</strong>,&nbsp;<strong>COPD</strong>, as well as&nbsp;<strong>active smokers</strong>. Hence, it is contraindicated in these condition.</p>\n</div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB1934",
      "difficulty": "easy"
    },
    {
      "text": "A 60-year-old man presents to the casualty with confusion, vomiting, and abdominal pain. His blood sugar levels are 421 mg/dl and urine ketones are 3+. He is started on IV normal saline and insulin infusion. Which of the following should he be monitored for?",
      "choices": [
        {
          "id": 1,
          "text": "Hypernatremia"
        },
        {
          "id": 2,
          "text": "Hyperkalemia"
        },
        {
          "id": 3,
          "text": "Hypokalemia"
        },
        {
          "id": 4,
          "text": "Hyponatremia"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>This clinical scenario is suggestive of <strong>diabetic ketoacidosis</strong>, which is treated with insulin infusion. <strong>Insulin </strong>causes&nbsp;an&nbsp;<strong>intracellular shift</strong>&nbsp;of&nbsp;K<sup>+</sup>&nbsp;ions resulting in a decreased extracellular K<sup>+</sup>&nbsp;ion concentration. This results in <strong>hypokalemia.</strong></p>\n<p>Non-diabetic clinical applications of insulin include:</p>\n<ul>\n<li>Treatment of hyperkalemia</li>\n<li>To determine the functions of the anterior pituitary&nbsp;</li>\n<li>To examine the completion of truncal vagotomy</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB1935",
      "difficulty": "easy"
    },
    {
      "text": "Dawn phenomenon is clinically suspected when a patient shows which of the following findings?",
      "choices": [
        {
          "id": 1,
          "text": "Early morning hyperglycemia with hypoglycemia at 3 am"
        },
        {
          "id": 2,
          "text": "Early morning hypoglycemia with normal blood glucose levels at 3 am"
        },
        {
          "id": 3,
          "text": "Early morning hyperglycemia with normal blood glucose levels at 3 am"
        },
        {
          "id": 4,
          "text": "Early morning hypoglycemia with hyperglycemia at 3 am"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Dawn</strong>&nbsp;<strong>phenomenon</strong> refers to&nbsp;normal blood glucose levels at 3 am followed by<strong>&nbsp;early morning hyperglycemia. </strong></p>\n<p>This occurs due to an early morning <strong>surge</strong> in plasma <strong>growth hormone</strong>&nbsp;and <strong>cortisol</strong> levels, which have an <strong>insulin-antagonistic</strong> action. In normal individuals, this is countered by increased early morning insulin secretion. However, in diabetic patients, insulin secretion is disrupted which results in the unopposed action of growth hormone. Hence, there will be resulting hyperglycemia.</p><hr><h3>Related Pearl: Dawn Phenomenon and Somogyi Phenomenon</h3><table>\n<tbody>\n<tr>\n<td>\n<p>&nbsp;</p>\n</td>\n<td>\n<p><strong>Dawn phenomenon</strong></p>\n</td>\n<td>\n<p><strong>Somogyi phenomenon</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Features</strong></p>\n</td>\n<td>\n<p>Early morning <strong>hyperglycaemia</strong></p>\n</td>\n<td>\n<p>Early morning <strong>hyperglycaemia</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>&nbsp;</strong></p>\n</td>\n<td>\n<p><strong>Normal blood glucose </strong>levels at 3 am</p>\n</td>\n<td>\n<p><strong>Hypoglycaemia</strong> at 3 am</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Mechanism</strong></p>\n</td>\n<td>\n<p>Early morning surge in growth hormone and cortisol which causes hyperglycemia</p>\n</td>\n<td>\n<p>Excessive night basal insulin dose &gt; hypoglycemia in middle of night &gt; triggers the release of counterregulatory hormones which causes hyperglycemia.</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Treatment </strong></p>\n</td>\n<td>\n<p><strong>Increase</strong> nighttime long-acting insulin dose</p>\n</td>\n<td>\n<p><strong>Decrease</strong> night time long-acting insulin dose</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB1936",
      "difficulty": "medium"
    },
    {
      "text": "A patient is said to have developed insulin resistance when the required insulin dosage is which of the following?",
      "choices": [
        {
          "id": 1,
          "text": "> 200 units per day"
        },
        {
          "id": 2,
          "text": "> 100 units per day"
        },
        {
          "id": 3,
          "text": "> 150 units per day"
        },
        {
          "id": 4,
          "text": "> 250 units per day"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>When a patient needs <strong>&gt; 200 units</strong> of insulin per day, they are said to have developed <strong>insulin resistance.</strong></p>\n<p>Some causes of insulin resistance are as follows:</p>\n<ul>\n<li>Werner syndrome</li>\n<li>Lipodystrophy syndrome</li>\n<li>Ataxia-telangiectasia</li>\n<li>Polycystic ovarian disease</li>\n</ul>\n<p>Insulin resistance can present as non-alcoholic fatty liver disease.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB1937",
      "difficulty": "medium"
    },
    {
      "text": "A 12-year-old child who is known to have type 1 diabetes mellitus presents with confusion and drowsiness. Her mother says that she seems to be breathing very fast. On examination, mucous membranes are dry and blood pressure is 70/50 mm Hg. Random blood glucose is 415 mg/dl and urine ketones are 4+. What is the next best step in management?",
      "choices": [
        {
          "id": 1,
          "text": "2-3 L of normal saline over 1-3 hours"
        },
        {
          "id": 2,
          "text": "Insulin infusion at 0.1 units/kg/hour"
        },
        {
          "id": 3,
          "text": "Arterial blood gas"
        },
        {
          "id": 4,
          "text": "Insulin bolus of 0.1 units/kg given IV"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The given clinical scenario is suggestive of <strong>diabetic ketoacidosis (DKA) </strong>and the first step is to assess the<strong> arterial blood gas</strong> (ABG) levels. This precedes correction of <strong>fluid balance</strong>, as assessment of the current status of the patient is necessary before beginning treatment. A <strong>baseline pH </strong>and <strong>electrolyte</strong> level must be obtained.</p>\n<p>Diabetic ketoacidosis is the most serious complication of <strong>type 1 diabetes mellitus.</strong> The symptoms include dehydration, nausea, vomiting, confusion, drowsiness, and coma in severe cases.</p>\n<p>In DKA, the<strong> insulin-to-glucagon ratio</strong> is <strong>decreased</strong> which promotes gluconeogenesis, glycogenolysis, and ketone body formation in the liver. Ketone bodies exist as ketoacids at physiological pH which are neutralized by bicarbonate. As bicarbonate stores are depleted, metabolic acidosis ensues. Increased lactic acid production also contributes to the acidosis.</p>\n<p>The <strong>diagnostic biochemical criteria </strong>for DKA includes:</p>\n<ul>\n<li>Hyperglycemia (&gt;250 mg/dL)</li>\n<li>Venous pH &lt;7.3</li>\n<li>Plasma/serum bicarbonate &lt;15-18 mmol/L</li>\n<li>Increased anion gap</li>\n<li>Ketonemia (beta-hydroxybutyrate [BOHB] &gt;3 mmol/L) and ketonuria</li>\n</ul>\n<p><strong>Signs</strong> of ketoacidosis:&nbsp;</p>\n<ul>\n<li>Kussmaul breathing (deep, heavy, non-labored rapid breathing)</li>\n<li>Fruity breath odor (acetone)</li>\n<li>Prolonged Q-T interval</li>\n<li>Diminished neurocognitive function</li>\n<li>Coma</li>\n</ul><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/18a61ed32ad34a81b485e17189c69f25x1280x2461.JPEG\" alt=\"Explanation Image\"><hr><h3>Related Pearl: Comparative Features of Diabetic Ketoacidosis and Hyperglycemic Hyperosmolar State</h3><table>\n<tbody>\n<tr>\n<td>\n<p><strong>&nbsp;</strong></p>\n</td>\n<td>\n<p><strong>DKA</strong></p>\n</td>\n<td>\n<p><strong>HHS</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Seen in </strong></p>\n</td>\n<td>\n<p>Type 1 DM</p>\n</td>\n<td>\n<p>Type 2 DM</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Clinical features</strong></p>\n</td>\n<td>\n<p>Abdominal pain</p>\n<p>Kussmaul respiration</p>\n<p>Fruity odour of breath</p>\n</td>\n<td>\n<p>Altered sensorium</p>\n<p>Coma</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Glucose (mg/dL)</strong></p>\n</td>\n<td>\n<p>250&ndash;600</p>\n</td>\n<td>\n<p>600&ndash;1200</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Sodium</strong></p>\n</td>\n<td>\n<p>120&ndash;125</p>\n</td>\n<td>\n<p>135&ndash;145</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Osmolality </strong></p>\n</td>\n<td>\n<p>300&ndash;320</p>\n</td>\n<td>\n<p>330&ndash;380</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Plasma Ketones</strong></p>\n</td>\n<td>\n<p>++++</p>\n</td>\n<td>\n<p>+/-</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Serum Bicarbonate</strong></p>\n</td>\n<td>\n<p>&lt; 15 meq/ L</p>\n</td>\n<td>\n<p>Normal to slightly &darr;</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Arterial pH </strong></p>\n</td>\n<td>\n<p>6.8&ndash;7.3</p>\n</td>\n<td>\n<p>&gt;7.3</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Arterial pCO<sub>2 </sub>(mmHg)</strong></p>\n</td>\n<td>\n<p>20&ndash;30</p>\n</td>\n<td>\n<p>Normal</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Anion Gap</strong></p>\n</td>\n<td>\n<p><strong>&uarr;</strong></p>\n</td>\n<td>\n<p>Normal to slightly &uarr;</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD3873",
      "difficulty": "hard"
    },
    {
      "text": "Which of the following is responsible for the elevated levels of TG and VLDL in diabetes mellitus?",
      "choices": [
        {
          "id": 1,
          "text": "Increased activity of lipoprotein lipase and decreased activity of hormone sensitive lipase"
        },
        {
          "id": 2,
          "text": "Increased activity of hormone sensitive lipase and decreased lipoprotein lipase activity"
        },
        {
          "id": 3,
          "text": "Increase in peripheral function of LDL receptors"
        },
        {
          "id": 4,
          "text": "Increased in activity of hepatic lipase"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<div class=\"ng-scope\">\n<div class=\"ng-scope\">\n<p>The <strong>elevated</strong> levels of <strong>triglycerides</strong> (TG) and <strong>very low-density lipoproteins</strong> (VLDL) in <strong>diabetes mellitus</strong> (DM) are due to <strong>decreased activity</strong> of <strong>lipoprotein lipase</strong> (LpL) and <strong>increased activity</strong> of <strong>hormone-sensitive lipase</strong> (HSL).</p>\n<p><strong>Insulin</strong> <strong>normally</strong> has an <strong>inhibitory</strong> action on <strong>HSL</strong> and <strong>induces LpL</strong> on capillary walls. There is an absolute or relative deficiency of insulin in DM. In <strong>DM</strong>, the <strong>activity</strong> of <strong>LpL</strong> is <strong>decreased</strong> and <strong>HSL</strong> is <strong>increased</strong>.</p>\n<p>The increased activity of <strong>HSL</strong> results in <strong>increased mobilisation</strong> of <strong>fat stores</strong> towards <strong>lipolysis</strong> releasing fatty acids. These fatty acids are <strong>partly cleared</strong> <strong>by </strong>the<strong> liver</strong>, resulting in <strong>increased synthesis</strong> of <strong>VLDL</strong> and <strong>TG</strong>, resulting in <strong>dyslipidemia</strong>. They can <strong>accumulate</strong> in the liver, resulting in <strong>steatosis</strong> (non-alcoholic fatty liver disease).</p>\n<p>The reduced activity of LpL prevents the clearing of TG and VLDL in the bloodstream and their levels remain elevated.</p>\n</div>\n</div><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/930c5ce53b9a48df908e15bf24113255x800x552.JPEG\" alt=\"Explanation Image\"><hr><h3>Related Pearl: Hormone sensitive lipase  Vs lipoprotein lipase</h3><table>\n<tbody>\n<tr>\n<td>&nbsp;</td>\n<td>&nbsp;HSL</td>\n<td>&nbsp;Lipoprotein lipase</td>\n</tr>\n<tr>\n<td>Location</td>\n<td>&nbsp;Adipocyte</td>\n<td>&nbsp;Capillaries</td>\n</tr>\n<tr>\n<td>Action</td>\n<td>&nbsp;Hydrolyse TAG in adipose&nbsp; &nbsp;tissue</td>\n<td>&nbsp;Hydrolyse TAG in chylomicron , VLDL</td>\n</tr>\n<tr>\n<td>Acts in the state of</td>\n<td>&nbsp;Fasting (Glucagon)</td>\n<td>&nbsp;Fed (Insulin)</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA1486",
      "difficulty": "medium"
    },
    {
      "text": "In a PHC, which of the following initial screening tests are used to diagnose diabetes?<div class='question-desc-html'><ol>\n<li>HbA1c &gt;6.5</li>\n<li>Fasting blood sugar &gt;126mg/dL</li>\n<li>Random blood sugar &gt;200mg/dL</li>\n<li>2 hour post glucose load blood sugar</li>\n</ol></div>",
      "choices": [
        {
          "id": 1,
          "text": "1 and 2"
        },
        {
          "id": 2,
          "text": "2 and 3"
        },
        {
          "id": 3,
          "text": "2 and 4"
        },
        {
          "id": 4,
          "text": "1, 2 and 3"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>Fasting blood sugar<strong> &gt;126 mg/dL</strong> and 2-hour postprandial blood sugar<strong> &gt;200 mg/dl</strong> can be used as screening tests for diabetes in a primary health center (PHC).</p>\n<p><strong>HbA1c</strong> estimation is usually unavailable for screening at many PHCs due to low resources. In India, facilities for HbA1c estimation are usually available only at <strong>tertiary centers.</strong></p>\n<p>Random blood sugar <strong>&gt;200 mg/dL</strong> can be used for diagnosis only if the patient presents with symptoms of diabetes, hence it is <strong>not a useful screening test.</strong></p><hr><h3>Related Pearl: ADA criteria for Diagnosis of Diabetes mellitus</h3><p><strong>Any one</strong> of the following:</p>\n<ul>\n<li><strong>Symptoms</strong> of diabetes <strong>plus</strong> Random Blood Glucose concentration <strong>&ge;</strong> <strong>200 mg/dL.</strong></li>\n<li><strong>Fasting plasma</strong> glucose <strong>&ge;</strong> <strong>126 </strong>mg/dL.&nbsp;Fasting is defined as no caloric intake for at least 8 hours.</li>\n<li>Haemoglobin <strong>A1c </strong><strong>&ge;6.</strong><strong>5%</strong></li>\n<li><strong>2-hour</strong> plasma <strong>glucose </strong><strong>&ge;</strong> <strong>200 mg/dL</strong> during an <strong>oral glucose tolerance test.</strong></li>\n</ul>\n<p>Note: In the absence of unequivocal hyperglycemia and acute metabolic decompensation, these criteria should be <strong>confirmed by repeat testing</strong> on a different day.</p><hr><h3>Related Pearl: Abnormal Glucose Homeostasis</h3><p>Individuals without overt diabetes can have <strong>abnormal glucose homeostasis.&nbsp;</strong>It is also&nbsp;called <strong>prediabetes</strong> or intermediate hyperglycemia. These people are at an increased risk of developing diabetes<strong>&nbsp;</strong>mellitus. Three categories of abnormal glucose homeostasis have been defined:</p>\n<ul>\n<li class=\"bulletIndent2\">Impaired glucose tolerance&nbsp;(IGT) &ndash;&nbsp;blood glucose levels between 140 and 199 mg/dL following an oral glucose challenge</li>\n<li class=\"bulletIndent2\">Impaired fasting glucose&nbsp;(IFG) &ndash; fasting<strong>&nbsp;</strong>blood glucose 100 to 125&nbsp;<span class=\"nowrap\">mg/dL</span>&nbsp;</li>\n<li class=\"bulletIndent2\">HbA1c&nbsp;&ndash; 5.7-6.4%</li>\n</ul>\n<p class=\"bulletIndent2\">Please&nbsp;note that impaired glucose tolerance and impaired fasting glucose are two distinct entities.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF0764",
      "difficulty": "hard"
    }
  ]
}